Michael Greenwood

Feature Writer

B.Sc. Chemistry, M.Sc. Drug Design and Discovery

Michael graduated from the University of Salford with a PhD in Biochemistry in 2023, and has keen research interests towards nanotechnology and its application to biological systems. Michael has written on a wide range of science communication and news topics within the life sciences and related fields since 2019, and engages extensively with current developments in journal publications.

Articles from Michael

Is transposable element expression affected by SARS-CoV-2 infection?

A study by researchers in Israel aims to establish whether TE expression is altered in SARS-CoV-2 infected cells, and explores the implications for host immune response.

1 Mar 2021

Exploring Preclinical Cancer Models

Researchers have developed a variety of cancer models that allow each aspect of a tumor to be analyzed at the in vitro and in vivo levels.

26 Feb 2021

SARS-CoV-2 ORF7a mutation limits host immune suppression, finds study

Researchers have identified a high variability in the C-terminal end of ORF7a in SARS-CoV-2 sequences collected from around the globe. They noted that mutations result in a defective suppression of interferon and lowered replication rate.

25 Feb 2021

SNX-5422 could make an effective COVID-19 prophylactic, says study

SNX-5422 is a heat shock protein 90 (Hsp90) inhibitor currently undergoing clinical trials as a cancer therapeutic. A recent study examines the applicability of repurposing the drug towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication inhibition.

25 Feb 2021

Full characterization of mammalian-produced SARS-CoV-2 receptor binding domains

A research paper recently uploaded to the preprint server bioRxiv by Dominguez-Vega et al. (23rd Feb, 2021) describes an in-depth structural analysis of the RBD of the spike protein expressed in mammalian Chinese hamster ovary (CHO) cells and human embryonic kidney (HEK293) cells, providing a new understanding of protein structure and function.

24 Feb 2021

Mapping the dominance of the SARS-CoV-2 UK variant in Europe

A research paper recently uploaded to the preprint server medRxiv* by Vespignani et al. (February 22nd, 2021) uses mathematical models to map the spread of this lineage across Europe, establishing that a 50% increase to the transmissibility of the variant would allow it to become dominant in major metropolitan areas by the end of March 2021.

24 Feb 2021

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

A paper recently uploaded to the preprint server bioRxiv by researchers at Chapman University in California (Feb 22nd, 2021) utilized computational methods to screen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants for affinity with the angiotensin-converting enzyme 2 (ACE2) receptor and monoclonal antibodies REG10987 and REG10933.

23 Feb 2021

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

A new research paper recently uploaded to the preprint server bioRxiv by Jesse D. Bloom et al. (22nd Feb 2021) aims to map all of the currently circulating SARS-CoV-2 lineages with resistance towards LY-CoV555 and LY-CoV016, and document the specific mutations that confer resistance, ultimately suggesting that future monoclonal antibody cocktails should target a more diverse range of epitopes.

23 Feb 2021

Incidence of cardiometabolic and pulmonary events in UK has lowered due to COVID-19

A team of researchers from the University of Oxford, the London School of Hygiene and Tropical Medicine and other institutions recently analyzed extensive data collected by NHS England to reveal any association between SARS-CoV-2 infection and cardiometabolic or respiratory events.

23 Feb 2021

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

A recent study by researchers at Tel Aviv University describes the UK variant’s rise to dominance in Israel. It also assesses the efficacy of the testing and vaccination programs employed by the government.

23 Feb 2021